| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 69 | 2023 | 2118 | 7.550 |
Why?
|
| Brain | 70 | 2023 | 1663 | 6.050 |
Why?
|
| Cognitive Dysfunction | 45 | 2023 | 1065 | 5.340 |
Why?
|
| Aging | 66 | 2023 | 1550 | 4.560 |
Why?
|
| Aged, 80 and over | 135 | 2023 | 4857 | 3.970 |
Why?
|
| Independent Living | 20 | 2023 | 318 | 3.940 |
Why?
|
| Cognition | 48 | 2023 | 1353 | 3.720 |
Why?
|
| Aged | 132 | 2023 | 9278 | 3.250 |
Why?
|
| Cerebral Amyloid Angiopathy | 8 | 2023 | 113 | 3.080 |
Why?
|
| Cognition Disorders | 30 | 2023 | 1003 | 3.010 |
Why?
|
| Health Literacy | 9 | 2023 | 109 | 2.980 |
Why?
|
| TDP-43 Proteinopathies | 13 | 2023 | 110 | 2.580 |
Why?
|
| Female | 142 | 2023 | 15728 | 2.540 |
Why?
|
| Male | 141 | 2023 | 15292 | 2.520 |
Why?
|
| Cohort Studies | 47 | 2023 | 1926 | 2.300 |
Why?
|
| Humans | 166 | 2023 | 28435 | 2.230 |
Why?
|
| Membrane Transport Proteins | 4 | 2017 | 57 | 2.080 |
Why?
|
| Longitudinal Studies | 51 | 2023 | 1384 | 1.900 |
Why?
|
| DNA Methylation | 8 | 2021 | 165 | 1.840 |
Why?
|
| Amyloid beta-Peptides | 9 | 2023 | 327 | 1.620 |
Why?
|
| Dementia | 17 | 2023 | 575 | 1.590 |
Why?
|
| Neuropsychological Tests | 39 | 2022 | 1226 | 1.540 |
Why?
|
| Parkinsonian Disorders | 11 | 2023 | 226 | 1.520 |
Why?
|
| Apolipoprotein E4 | 8 | 2019 | 264 | 1.490 |
Why?
|
| Autopsy | 23 | 2022 | 343 | 1.410 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2018 | 390 | 1.360 |
Why?
|
| Hippocampus | 8 | 2020 | 278 | 1.340 |
Why?
|
| Apolipoproteins E | 9 | 2020 | 252 | 1.330 |
Why?
|
| Lewy Bodies | 14 | 2021 | 194 | 1.330 |
Why?
|
| Decision Making | 12 | 2023 | 226 | 1.220 |
Why?
|
| Neurodegenerative Diseases | 5 | 2021 | 124 | 1.170 |
Why?
|
| Financial Management | 5 | 2020 | 23 | 1.080 |
Why?
|
| DNA-Binding Proteins | 13 | 2023 | 274 | 1.070 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2023 | 1143 | 1.060 |
Why?
|
| Nervous System Diseases | 3 | 2023 | 121 | 1.030 |
Why?
|
| Disabled Persons | 4 | 2023 | 125 | 0.990 |
Why?
|
| Cerebrovascular Disorders | 7 | 2022 | 134 | 0.950 |
Why?
|
| Disease Progression | 17 | 2021 | 718 | 0.940 |
Why?
|
| Cognitive Reserve | 2 | 2022 | 39 | 0.930 |
Why?
|
| Polymorphism, Genetic | 2 | 2017 | 62 | 0.930 |
Why?
|
| Prefrontal Cortex | 6 | 2023 | 137 | 0.920 |
Why?
|
| Nerve Tissue Proteins | 4 | 2020 | 155 | 0.910 |
Why?
|
| Cerebral Cortex | 3 | 2021 | 161 | 0.900 |
Why?
|
| Mobility Limitation | 3 | 2021 | 94 | 0.890 |
Why?
|
| Cerebral Infarction | 6 | 2016 | 148 | 0.890 |
Why?
|
| Government | 1 | 2023 | 3 | 0.870 |
Why?
|
| Proteomics | 4 | 2023 | 93 | 0.810 |
Why?
|
| Medicare | 1 | 2023 | 121 | 0.810 |
Why?
|
| Neurofibrillary Tangles | 5 | 2023 | 193 | 0.800 |
Why?
|
| Membrane Proteins | 4 | 2021 | 171 | 0.800 |
Why?
|
| Plaque, Amyloid | 4 | 2019 | 146 | 0.800 |
Why?
|
| Memory, Episodic | 9 | 2023 | 116 | 0.790 |
Why?
|
| White Matter | 7 | 2022 | 134 | 0.790 |
Why?
|
| Cognitive Aging | 5 | 2021 | 78 | 0.790 |
Why?
|
| Elder Abuse | 1 | 2022 | 36 | 0.750 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2020 | 65 | 0.750 |
Why?
|
| Proteome | 3 | 2023 | 42 | 0.690 |
Why?
|
| Proteins | 1 | 2020 | 67 | 0.690 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 183 | 0.680 |
Why?
|
| Risk Factors | 16 | 2022 | 2408 | 0.670 |
Why?
|
| Educational Status | 11 | 2021 | 300 | 0.670 |
Why?
|
| Brain Infarction | 2 | 2017 | 75 | 0.670 |
Why?
|
| Genetic Variation | 2 | 2017 | 97 | 0.660 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 13 | 0.650 |
Why?
|
| Haplotypes | 3 | 2020 | 59 | 0.640 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 4 | 2019 | 26 | 0.620 |
Why?
|
| Exercise | 8 | 2023 | 473 | 0.620 |
Why?
|
| Frontotemporal Lobar Degeneration | 2 | 2018 | 29 | 0.610 |
Why?
|
| Gene Expression | 2 | 2019 | 202 | 0.580 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2015 | 34 | 0.580 |
Why?
|
| Neuropathology | 5 | 2023 | 82 | 0.570 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 87 | 0.560 |
Why?
|
| Motor Activity | 6 | 2019 | 329 | 0.560 |
Why?
|
| Residence Characteristics | 9 | 2018 | 215 | 0.560 |
Why?
|
| Literacy | 1 | 2017 | 16 | 0.550 |
Why?
|
| Neurons | 6 | 2022 | 342 | 0.550 |
Why?
|
| Apolipoprotein E3 | 1 | 2017 | 16 | 0.550 |
Why?
|
| Homozygote | 1 | 2017 | 21 | 0.550 |
Why?
|
| Sclerosis | 5 | 2019 | 66 | 0.540 |
Why?
|
| Genotype | 6 | 2018 | 359 | 0.540 |
Why?
|
| Follow-Up Studies | 15 | 2020 | 1859 | 0.540 |
Why?
|
| RNA, Messenger | 1 | 2017 | 308 | 0.540 |
Why?
|
| Brain Diseases | 4 | 2021 | 67 | 0.540 |
Why?
|
| Intracranial Arteriosclerosis | 4 | 2022 | 53 | 0.530 |
Why?
|
| Genetic Association Studies | 4 | 2019 | 85 | 0.520 |
Why?
|
| Olfaction Disorders | 4 | 2021 | 49 | 0.510 |
Why?
|
| tau Proteins | 6 | 2023 | 235 | 0.510 |
Why?
|
| Age Factors | 13 | 2021 | 781 | 0.500 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 116 | 0.480 |
Why?
|
| Quality of Life | 3 | 2015 | 661 | 0.480 |
Why?
|
| Antiporters | 1 | 2015 | 6 | 0.480 |
Why?
|
| HLA-DRB5 Chains | 1 | 2015 | 6 | 0.480 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 17 | 0.480 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2015 | 17 | 0.480 |
Why?
|
| Genetic Loci | 1 | 2015 | 51 | 0.470 |
Why?
|
| Markov Chains | 2 | 2015 | 32 | 0.460 |
Why?
|
| Arteriolosclerosis | 4 | 2023 | 77 | 0.460 |
Why?
|
| Choice Behavior | 4 | 2019 | 46 | 0.460 |
Why?
|
| Death | 4 | 2020 | 47 | 0.440 |
Why?
|
| Delay Discounting | 3 | 2023 | 24 | 0.430 |
Why?
|
| Genome-Wide Association Study | 9 | 2019 | 283 | 0.410 |
Why?
|
| United States | 9 | 2023 | 2200 | 0.400 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 86 | 0.400 |
Why?
|
| Neuropeptides | 2 | 2023 | 27 | 0.390 |
Why?
|
| Models, Psychological | 1 | 2012 | 77 | 0.390 |
Why?
|
| Fraud | 3 | 2022 | 21 | 0.390 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2011 | 5 | 0.390 |
Why?
|
| Motor Disorders | 2 | 2023 | 23 | 0.380 |
Why?
|
| Atherosclerosis | 2 | 2023 | 55 | 0.380 |
Why?
|
| Risk Assessment | 2 | 2015 | 677 | 0.380 |
Why?
|
| Hypertension | 3 | 2022 | 245 | 0.370 |
Why?
|
| Lewy Body Disease | 3 | 2021 | 100 | 0.370 |
Why?
|
| Memory | 8 | 2021 | 302 | 0.370 |
Why?
|
| Linear Models | 5 | 2020 | 251 | 0.360 |
Why?
|
| HSP27 Heat-Shock Proteins | 3 | 2019 | 18 | 0.350 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 933 | 0.350 |
Why?
|
| Incidence | 6 | 2021 | 773 | 0.350 |
Why?
|
| Biomarkers | 4 | 2023 | 596 | 0.330 |
Why?
|
| Crime Victims | 2 | 2022 | 33 | 0.320 |
Why?
|
| Alleles | 5 | 2018 | 221 | 0.320 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 352 | 0.320 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2019 | 284 | 0.310 |
Why?
|
| Severity of Illness Index | 6 | 2021 | 988 | 0.290 |
Why?
|
| Middle Aged | 20 | 2021 | 9270 | 0.280 |
Why?
|
| Gait | 2 | 2023 | 413 | 0.280 |
Why?
|
| Memory Disorders | 3 | 2019 | 162 | 0.270 |
Why?
|
| Movement Disorders | 2 | 2021 | 90 | 0.270 |
Why?
|
| Reward | 2 | 2019 | 23 | 0.260 |
Why?
|
| Heterozygote | 3 | 2018 | 102 | 0.260 |
Why?
|
| Neuroimaging | 3 | 2021 | 128 | 0.250 |
Why?
|
| Sex Factors | 9 | 2020 | 475 | 0.250 |
Why?
|
| Logistic Models | 5 | 2020 | 396 | 0.250 |
Why?
|
| Prospective Studies | 10 | 2021 | 1809 | 0.250 |
Why?
|
| Genome, Human | 2 | 2016 | 50 | 0.250 |
Why?
|
| Blood Pressure | 3 | 2022 | 208 | 0.240 |
Why?
|
| Phenotype | 3 | 2023 | 313 | 0.240 |
Why?
|
| GPI-Linked Proteins | 2 | 2023 | 21 | 0.230 |
Why?
|
| Substantia Nigra | 3 | 2021 | 125 | 0.230 |
Why?
|
| Neural Pathways | 3 | 2014 | 65 | 0.230 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 157 | 0.230 |
Why?
|
| Illinois | 4 | 2020 | 246 | 0.230 |
Why?
|
| Actigraphy | 5 | 2020 | 99 | 0.220 |
Why?
|
| CpG Islands | 4 | 2021 | 54 | 0.220 |
Why?
|
| Parkinson Disease | 2 | 2023 | 859 | 0.220 |
Why?
|
| Brain Mapping | 3 | 2014 | 150 | 0.220 |
Why?
|
| Government Agencies | 1 | 2023 | 4 | 0.220 |
Why?
|
| Temporal Lobe | 3 | 2020 | 84 | 0.220 |
Why?
|
| Mortality | 3 | 2021 | 90 | 0.220 |
Why?
|
| Antibodies, Antiphospholipid | 2 | 2014 | 23 | 0.220 |
Why?
|
| Frail Elderly | 2 | 2014 | 53 | 0.210 |
Why?
|
| Limbic Encephalitis | 1 | 2023 | 12 | 0.210 |
Why?
|
| Memory, Short-Term | 3 | 2019 | 100 | 0.210 |
Why?
|
| Resilience, Psychological | 1 | 2023 | 30 | 0.210 |
Why?
|
| Mental Status and Dementia Tests | 3 | 2020 | 69 | 0.210 |
Why?
|
| Atrophy | 2 | 2021 | 93 | 0.210 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 362 | 0.210 |
Why?
|
| Risk | 4 | 2019 | 205 | 0.210 |
Why?
|
| Nerve Growth Factors | 1 | 2023 | 37 | 0.210 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 53 | 0.200 |
Why?
|
| Life Style | 2 | 2021 | 201 | 0.200 |
Why?
|
| Psychomotor Performance | 2 | 2021 | 213 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 56 | 0.200 |
Why?
|
| Stem Cells | 1 | 2022 | 41 | 0.200 |
Why?
|
| Sleep Wake Disorders | 2 | 2014 | 130 | 0.190 |
Why?
|
| Mitochondrial Proteins | 1 | 2021 | 42 | 0.190 |
Why?
|
| Blood Glucose | 1 | 2022 | 108 | 0.190 |
Why?
|
| Sex Characteristics | 2 | 2022 | 118 | 0.190 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2021 | 9 | 0.190 |
Why?
|
| Perception | 2 | 2019 | 78 | 0.190 |
Why?
|
| Awareness | 2 | 2019 | 45 | 0.190 |
Why?
|
| Time Factors | 6 | 2015 | 1491 | 0.190 |
Why?
|
| Risk-Taking | 2 | 2011 | 35 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 61 | 0.180 |
Why?
|
| Sleep | 3 | 2014 | 355 | 0.180 |
Why?
|
| Age of Onset | 1 | 2021 | 99 | 0.180 |
Why?
|
| beta-Lactamases | 1 | 2021 | 85 | 0.180 |
Why?
|
| Protein Interaction Maps | 2 | 2018 | 15 | 0.180 |
Why?
|
| Amygdala | 1 | 2021 | 41 | 0.180 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2020 | 5 | 0.180 |
Why?
|
| Actinin | 1 | 2020 | 7 | 0.180 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 10 | 0.180 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 281 | 0.180 |
Why?
|
| Epoxide Hydrolases | 1 | 2020 | 11 | 0.180 |
Why?
|
| Molecular Chaperones | 1 | 2020 | 13 | 0.180 |
Why?
|
| Chronobiology Disorders | 1 | 2020 | 16 | 0.180 |
Why?
|
| Social Segregation | 1 | 2020 | 7 | 0.180 |
Why?
|
| Peptides | 1 | 2021 | 103 | 0.170 |
Why?
|
| RNA Splicing Factors | 1 | 2020 | 5 | 0.170 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2020 | 42 | 0.170 |
Why?
|
| Mental Status Schedule | 2 | 2017 | 93 | 0.170 |
Why?
|
| Self Concept | 1 | 2020 | 42 | 0.170 |
Why?
|
| Child Development | 1 | 2020 | 75 | 0.160 |
Why?
|
| Olfactory Bulb | 1 | 2019 | 18 | 0.160 |
Why?
|
| Adenylate Kinase | 1 | 2019 | 6 | 0.160 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 7 | 0.160 |
Why?
|
| Neocortex | 1 | 2019 | 31 | 0.160 |
Why?
|
| Stroke | 1 | 2023 | 276 | 0.160 |
Why?
|
| Depression | 2 | 2013 | 452 | 0.160 |
Why?
|
| Body Fluid Compartments | 1 | 2019 | 5 | 0.160 |
Why?
|
| Prodromal Symptoms | 1 | 2019 | 18 | 0.160 |
Why?
|
| Self Report | 5 | 2022 | 221 | 0.160 |
Why?
|
| Transcriptome | 1 | 2019 | 86 | 0.160 |
Why?
|
| Body Composition | 1 | 2019 | 69 | 0.150 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 39 | 0.150 |
Why?
|
| Adipose Tissue | 1 | 2019 | 78 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 169 | 0.150 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2017 | 11 | 0.150 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 23 | 0.150 |
Why?
|
| alpha-Macroglobulins | 1 | 2017 | 12 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 43 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 47 | 0.140 |
Why?
|
| Depressive Disorder | 1 | 2019 | 186 | 0.140 |
Why?
|
| Prognosis | 2 | 2018 | 825 | 0.140 |
Why?
|
| Learning | 1 | 2018 | 73 | 0.140 |
Why?
|
| Diagnosis | 1 | 2017 | 24 | 0.140 |
Why?
|
| Genetic Linkage | 1 | 2017 | 58 | 0.140 |
Why?
|
| Genotyping Techniques | 1 | 2017 | 9 | 0.140 |
Why?
|
| Locus Coeruleus | 2 | 2013 | 22 | 0.130 |
Why?
|
| Postmortem Changes | 1 | 2016 | 31 | 0.130 |
Why?
|
| Chromatin | 1 | 2016 | 17 | 0.130 |
Why?
|
| ROC Curve | 1 | 2016 | 145 | 0.130 |
Why?
|
| Gray Matter | 1 | 2016 | 51 | 0.130 |
Why?
|
| Smell | 1 | 2015 | 17 | 0.130 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 704 | 0.130 |
Why?
|
| Chicago | 4 | 2021 | 947 | 0.130 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2016 | 48 | 0.120 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 397 | 0.120 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 608 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 46 | 0.120 |
Why?
|
| Preoptic Area | 1 | 2014 | 6 | 0.120 |
Why?
|
| Ankyrins | 1 | 2014 | 4 | 0.120 |
Why?
|
| Personality | 1 | 2015 | 54 | 0.120 |
Why?
|
| Gyrus Cinguli | 1 | 2014 | 14 | 0.110 |
Why?
|
| Harm Reduction | 1 | 2014 | 6 | 0.110 |
Why?
|
| Poverty | 1 | 2015 | 100 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2014 | 106 | 0.110 |
Why?
|
| Mesencephalon | 1 | 2013 | 26 | 0.110 |
Why?
|
| Cerebellum | 1 | 2013 | 46 | 0.110 |
Why?
|
| Cholinergic Antagonists | 1 | 2013 | 11 | 0.110 |
Why?
|
| Longevity | 1 | 2013 | 30 | 0.110 |
Why?
|
| Knee Joint | 1 | 2019 | 746 | 0.110 |
Why?
|
| Brain Stem | 1 | 2013 | 19 | 0.100 |
Why?
|
| Comorbidity | 3 | 2021 | 500 | 0.100 |
Why?
|
| Nerve Degeneration | 1 | 2013 | 49 | 0.100 |
Why?
|
| Psychomotor Disorders | 1 | 2013 | 11 | 0.100 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 15 | 0.100 |
Why?
|
| Personal Satisfaction | 1 | 2013 | 44 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2013 | 44 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 3 | 2022 | 83 | 0.100 |
Why?
|
| Child Abuse | 1 | 2012 | 35 | 0.100 |
Why?
|
| Emotions | 1 | 2012 | 78 | 0.100 |
Why?
|
| Regression Analysis | 3 | 2018 | 266 | 0.090 |
Why?
|
| Wakefulness | 1 | 2011 | 98 | 0.090 |
Why?
|
| Odorants | 1 | 2010 | 22 | 0.090 |
Why?
|
| Motor Skills | 2 | 2021 | 52 | 0.090 |
Why?
|
| Reaction Time | 2 | 2021 | 106 | 0.090 |
Why?
|
| Likelihood Functions | 1 | 2010 | 27 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2012 | 241 | 0.090 |
Why?
|
| Adult | 6 | 2022 | 8107 | 0.080 |
Why?
|
| Psychological Tests | 3 | 2015 | 53 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2016 | 326 | 0.080 |
Why?
|
| Fractals | 2 | 2019 | 21 | 0.080 |
Why?
|
| Probability | 2 | 2021 | 90 | 0.070 |
Why?
|
| Child | 3 | 2020 | 1421 | 0.070 |
Why?
|
| Neurologic Examination | 2 | 2020 | 114 | 0.070 |
Why?
|
| Tuberous Sclerosis | 2 | 2017 | 15 | 0.070 |
Why?
|
| Statistics as Topic | 2 | 2017 | 107 | 0.060 |
Why?
|
| Nerve Net | 2 | 2019 | 41 | 0.060 |
Why?
|
| Disability Evaluation | 2 | 2019 | 289 | 0.060 |
Why?
|
| Cell Count | 2 | 2014 | 79 | 0.060 |
Why?
|
| Rest | 2 | 2014 | 33 | 0.050 |
Why?
|
| Adaptor Protein Complex 1 | 1 | 2023 | 7 | 0.050 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2023 | 7 | 0.050 |
Why?
|
| RNA | 1 | 2023 | 37 | 0.050 |
Why?
|
| Infarction | 1 | 2023 | 30 | 0.050 |
Why?
|
| Hand Strength | 1 | 2023 | 60 | 0.050 |
Why?
|
| Triglycerides | 1 | 2022 | 61 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2023 | 60 | 0.050 |
Why?
|
| Cholesterol | 1 | 2022 | 64 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2022 | 85 | 0.050 |
Why?
|
| Individuality | 1 | 2022 | 24 | 0.050 |
Why?
|
| Social Class | 1 | 2022 | 67 | 0.050 |
Why?
|
| Epigenomics | 1 | 2021 | 19 | 0.050 |
Why?
|
| Causality | 1 | 2021 | 56 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 41 | 0.040 |
Why?
|
| Late Onset Disorders | 1 | 2020 | 6 | 0.040 |
Why?
|
| Southeastern United States | 1 | 2020 | 14 | 0.040 |
Why?
|
| Anisotropy | 1 | 2020 | 47 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2020 | 42 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2021 | 269 | 0.040 |
Why?
|
| Walking | 1 | 2023 | 260 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2020 | 62 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 47 | 0.040 |
Why?
|
| Lysosomes | 1 | 2020 | 26 | 0.040 |
Why?
|
| Myelin Sheath | 1 | 2020 | 26 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2020 | 63 | 0.040 |
Why?
|
| Adolescent | 2 | 2019 | 2309 | 0.040 |
Why?
|
| Young Adult | 2 | 2019 | 2070 | 0.040 |
Why?
|
| Space Perception | 1 | 2019 | 24 | 0.040 |
Why?
|
| Frailty | 1 | 2020 | 35 | 0.040 |
Why?
|
| Reference Values | 1 | 2020 | 194 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 207 | 0.040 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2019 | 3 | 0.040 |
Why?
|
| ADAMTS Proteins | 1 | 2019 | 5 | 0.040 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2019 | 5 | 0.040 |
Why?
|
| Versicans | 1 | 2019 | 7 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 81 | 0.040 |
Why?
|
| Electric Impedance | 1 | 2019 | 27 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2019 | 25 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2019 | 46 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2019 | 35 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 81 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 12 | 0.040 |
Why?
|
| Financing, Personal | 1 | 2018 | 20 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 146 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2019 | 136 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 119 | 0.040 |
Why?
|
| alpha-Synuclein | 1 | 2018 | 133 | 0.030 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2016 | 5 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 2016 | 12 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2016 | 15 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 54 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 27 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2016 | 81 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 75 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 16 | 0.030 |
Why?
|
| Amyloid | 1 | 2015 | 56 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 73 | 0.030 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2014 | 7 | 0.030 |
Why?
|
| Phosphatidylserines | 1 | 2014 | 7 | 0.030 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2014 | 7 | 0.030 |
Why?
|
| Galanin | 1 | 2014 | 4 | 0.030 |
Why?
|
| Autoantigens | 1 | 2014 | 25 | 0.030 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 2014 | 13 | 0.030 |
Why?
|
| Cerebral Arteries | 1 | 2014 | 25 | 0.030 |
Why?
|
| Amyloidosis | 1 | 2014 | 25 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 110 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2015 | 211 | 0.030 |
Why?
|
| Histones | 1 | 2014 | 28 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2014 | 15 | 0.030 |
Why?
|
| Raphe Nuclei | 1 | 2013 | 7 | 0.030 |
Why?
|
| Ventral Tegmental Area | 1 | 2013 | 9 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 310 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 67 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2014 | 54 | 0.030 |
Why?
|
| Medicare Part D | 1 | 2013 | 7 | 0.030 |
Why?
|
| Sleep Deprivation | 1 | 2014 | 74 | 0.030 |
Why?
|
| Religion | 1 | 2013 | 42 | 0.030 |
Why?
|
| Catholicism | 1 | 2013 | 20 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Language Tests | 1 | 2013 | 33 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 166 | 0.030 |
Why?
|
| Health Surveys | 1 | 2013 | 88 | 0.030 |
Why?
|
| Executive Function | 1 | 2013 | 115 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2013 | 129 | 0.030 |
Why?
|
| Mutation | 1 | 2014 | 354 | 0.020 |
Why?
|
| Clergy | 1 | 2013 | 92 | 0.020 |
Why?
|
| Income | 1 | 2012 | 78 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 441 | 0.020 |
Why?
|
| Games, Experimental | 1 | 2011 | 7 | 0.020 |
Why?
|
| Models, Biological | 1 | 2014 | 326 | 0.020 |
Why?
|
| Oxygen | 1 | 2011 | 73 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 689 | 0.020 |
Why?
|
| Health Status | 1 | 2012 | 224 | 0.020 |
Why?
|
| Parents | 1 | 2012 | 126 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 378 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 465 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 1216 | 0.020 |
Why?
|